Compare Medpace Holdings Inc (MEDP) vs PulteGroup, Inc. (PHM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs PulteGroup, Inc. — how do they compare? Medpace Holdings Inc trades at $597.39 (market cap $16.90B), while PulteGroup, Inc. trades at $129.46 (market cap $25.22B). The key difference: PulteGroup, Inc. is the larger of the two by market cap, and PulteGroup, Inc. pays a 0.79% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals.
| MEDP | PHM | |
|---|---|---|
Market Cap | $16.90B | $25.22B |
Sector | Technology | Consumer Cyclical |
52-Week High | $620.59 | $142.56 |
52-Week Low | $393.42 | $110.11 |
Enterprise Value | $16.52B | $25.64B |
Dividend Yield | — | 0.79% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MEDP trades at $596.98, down 0.9% on the day but near its 52-week highs. The stock shows strong technical momentum with bullish moving averages and recent golden cross formation. Fundamentally, the company delivered three consecutive quarterly earnings beats with Q2 2026 EPS of $4.25 beating expectations of $3.98. Revenue growth remains robust at 17.2% year-over-year in Q2 2026, supported by record net bookings and a $3.0 billion backlog.
MEDP presents a growth story with strong fundamentals but trades at premium valuations (P/E 35.58, P/S 6.27). The primary investment opportunity lies in continued execution on record bookings and backlog conversion. Key risks include the ongoing shareholder litigation investigation and potential valuation compression if growth moderates. Analyst consensus targets $599.57 with 21% buy ratings, suggesting limited near-term upside from current levels.
PulteGroup (PHM) trades at $129.35, down 0.54% today, with a bullish technical signal from moving averages and neutral oscillators. The company reported Q2 2026 EPS of $2.48, beating estimates, but revenue and margins face pressure. Analyst consensus is a Moderate Buy with a $137.20 price target, and recent news highlights operational expansion into Northwest Florida and workplace recognition.
The outlook remains cautiously optimistic supported by a solid balance sheet and community growth, though margin compression and housing market affordability challenges present near-term risks. The stock offers value with a P/E of 13.53, but investors should monitor earnings consistency and industry headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About PulteGroup, Inc.
PulteGroup Inc is one of the largest homebuilders in the United States, operating in 40 markets across 23 states. The company mainly builds single-family detached homes (85% of unit sales) and offers products to entry-level, move-up, and active-adult buyers. PulteGroup offers homebuyers mortgage financing and title agency services through its financial services segment. The company is headquartered in Atlanta.
Read more on PHM →
